-
1
-
-
0036882395
-
Serpin structure, mechanism, and function
-
Gettins PGW. Serpin structure, mechanism, and function. Chem Rev 2002; 102: 4751-803.
-
(2002)
Chem Rev
, vol.102
, pp. 4751-4803
-
-
Gettins, P.G.W.1
-
2
-
-
0021341098
-
Anticoagulantly active heparin-like molecules from the vascular tissue
-
Marcum JA, Rosenberg RD. Anticoagulantly active heparin-like molecules from the vascular tissue. Biochemistry 1984; 23: 1730-7.
-
(1984)
Biochemistry
, vol.23
, pp. 1730-1737
-
-
Marcum, J.A.1
Rosenberg, R.D.2
-
3
-
-
0026788099
-
A comparison of three heparin-binding serine proteinase inhibitors
-
Pratt CW, Whinna HC, Church FC. A comparison of three heparin-binding serine proteinase inhibitors. J Biol Chem 1992; 267: 8795-801.
-
(1992)
J Biol Chem
, vol.267
, pp. 8795-8801
-
-
Pratt, C.W.1
Whinna, H.C.2
Church, F.C.3
-
4
-
-
0037040926
-
Helix D elongation and allosteric activation of antithrombin
-
Belzar KJ, Zhou A, Carrell RW, Gettins PGW, Huntington JA. Helix D elongation and allosteric activation of antithrombin. J Biol Chem 2002; 277: 8551-8.
-
(2002)
J Biol Chem
, vol.277
, pp. 8551-8558
-
-
Belzar, K.J.1
Zhou, A.2
Carrell, R.W.3
Gettins, P.G.W.4
Huntington, J.A.5
-
5
-
-
0037108171
-
Specificity of the basic side chains of Lys114, Lys125, and Arg129 of antithrombin in heparin binding
-
Schedin-Weiss S, Arocas V, Bock SC, Olson ST, Björk I. Specificity of the basic side chains of Lys114, Lys125, and Arg129 of antithrombin in heparin binding. Biochemistry 2002; 41: 12369-76.
-
(2002)
Biochemistry
, vol.41
, pp. 12369-12376
-
-
Schedin-Weiss, S.1
Arocas, V.2
Bock, S.C.3
Olson, S.T.4
Björk, I.5
-
6
-
-
0030858409
-
Antithrombin: Molecular basis of deficiency
-
Bayston TA, Lane DA. Antithrombin: Molecular basis of deficiency. Thromb Haemost 1997; 78: 339-43.
-
(1997)
Thromb Haemost
, vol.78
, pp. 339-343
-
-
Bayston, T.A.1
Lane, D.A.2
-
7
-
-
0033578910
-
Antiangiogenic activity of the cleaved conformation of the serpin antithrombin
-
O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999; 285: 1926-8.
-
(1999)
Science
, vol.285
, pp. 1926-1928
-
-
O'Reilly, M.S.1
Pirie-Shepherd, S.2
Lane, W.S.3
Folkman, J.4
-
8
-
-
33744911983
-
Antiangiogenic antithrombin induces global changes in the gene expression profile of endothelial cells
-
Zhang W, Chuang YJ, Jin T, Swanson R, Xiong Y, Leung L, Olson ST. Antiangiogenic antithrombin induces global changes in the gene expression profile of endothelial cells. Cancer Res 2006; 66: 5047-55.
-
(2006)
Cancer Res
, vol.66
, pp. 5047-5055
-
-
Zhang, W.1
Chuang, Y.J.2
Jin, T.3
Swanson, R.4
Xiong, Y.5
Leung, L.6
Olson, S.T.7
-
10
-
-
23944454401
-
The heparin-binding site of antithrombin is crucial for antiangiogenic activity
-
Zhang W, Swanson R, Izaguirre G, Xiong Y, Lau LF, Olson ST. The heparin-binding site of antithrombin is crucial for antiangiogenic activity. Blood 2005; 106: 1621-8.
-
(2005)
Blood
, vol.106
, pp. 1621-1628
-
-
Zhang, W.1
Swanson, R.2
Izaguirre, G.3
Xiong, Y.4
Lau, L.F.5
Olson, S.T.6
-
11
-
-
33846025442
-
Antiangiogenic antithrombin blocks the heparan sulfate-dependent binding of proangiogenic growth factors to their endothelial cell receptors: Evidence for differential binding of antiangiogenic and anticoagulant forms of antithrombin to proangiogenic heparan sulfate domains
-
Zhang W, Swanson R, Xiong Y, Richard B, Olson ST. Antiangiogenic antithrombin blocks the heparan sulfate-dependent binding of proangiogenic growth factors to their endothelial cell receptors: evidence for differential binding of antiangiogenic and anticoagulant forms of antithrombin to proangiogenic heparan sulfate domains. J Biol Chem 2006; 281: 37302-10.
-
(2006)
J Biol Chem
, vol.281
, pp. 37302-37310
-
-
Zhang, W.1
Swanson, R.2
Xiong, Y.3
Richard, B.4
Olson, S.T.5
-
12
-
-
0037944105
-
Antithrombin reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production
-
Mizutani A, Okajima K, Uchiba M, Isobe H, Harada N, Mizutani S, Noguchi T. Antithrombin reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production. Blood 2003; 101: 3029-6.
-
(2003)
Blood
, vol.101
, pp. 3029-3036
-
-
Mizutani, A.1
Okajima, K.2
Uchiba, M.3
Isobe, H.4
Harada, N.5
Mizutani, S.6
Noguchi, T.7
-
13
-
-
0035865626
-
Cell-surface heparin sulfate proteoglycan-mediated regulation of human neutrophil migration by the serpin antithrombin III
-
Dunzendorfer S, Kaneider N, Rabensteiner A, Meiehofer C, Reinisch C, Romisch J, Wiedermann CJ. Cell-surface heparin sulfate proteoglycan-mediated regulation of human neutrophil migration by the serpin antithrombin III. Blood 2001; 97: 1079-85.
-
(2001)
Blood
, vol.97
, pp. 1079-1085
-
-
Dunzendorfer, S.1
Kaneider, N.2
Rabensteiner, A.3
Meiehofer, C.4
Reinisch, C.5
Romisch, J.6
Wiedermann, C.J.7
-
14
-
-
0034651773
-
Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli
-
Minnema MC, Chang ACK, Jansen PM, Lubbers YTP, Pratt BM, Whittaker BG, Taylor FB, Hack CE, Friedman B. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 2000; 95: 1117-23.
-
(2000)
Blood
, vol.95
, pp. 1117-1123
-
-
Minnema, M.C.1
Chang, A.C.K.2
Jansen, P.M.3
Lubbers, Y.T.P.4
Pratt, B.M.5
Whittaker, B.G.6
Taylor, F.B.7
Hack, C.E.8
Friedman, B.9
-
15
-
-
0035802223
-
Probing the molecular basis of factor Xa specificity by mutagenesis of the serpin, antithrombin
-
Rezaie AR, Yang L. Probing the molecular basis of factor Xa specificity by mutagenesis of the serpin, antithrombin. Biochem Biophys Acta 2001; 1528: 167-76.
-
(2001)
Biochem Biophys Acta
, vol.1528
, pp. 167-176
-
-
Rezaie, A.R.1
Yang, L.2
-
16
-
-
33846412233
-
Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma
-
Rezaie AR. Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma. Thromb Res 2006; 119: 481-8.
-
(2006)
Thromb Res
, vol.119
, pp. 481-488
-
-
Rezaie, A.R.1
-
17
-
-
46749084607
-
Protease activated receptor 1 (PAR-1) activation by thrombin is protective in human pulmonary artery endothelial cells if endothelial protein C receptor is occupied by its natural ligand
-
Bae J-S, Rezaie AR. Protease activated receptor 1 (PAR-1) activation by thrombin is protective in human pulmonary artery endothelial cells if endothelial protein C receptor is occupied by its natural ligand. Thromb Haemost 2008; 100: 101-9.
-
(2008)
Thromb Haemost
, vol.100
, pp. 101-109
-
-
Bae, J.-S.1
Rezaie, A.R.2
-
18
-
-
0035815747
-
Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis
-
Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001; 276: 11199-203.
-
(2001)
J Biol Chem
, vol.276
, pp. 11199-11203
-
-
Joyce, D.E.1
Gelbert, L.2
Ciaccia, A.3
DeHoff, B.4
Grinnell, B.W.5
-
19
-
-
33847329718
-
Receptors of the protein C activation and activated protein C signaling pathways are co-localized in lipid rafts of endothelial cells
-
Bae J-S, Yang L, Rezaie AR. Receptors of the protein C activation and activated protein C signaling pathways are co-localized in lipid rafts of endothelial cells. Proc Natl Acad Sci USA 2007; 104: 2867-72.
-
(2007)
Proc Natl Acad Sci USA
, vol.104
, pp. 2867-2872
-
-
Bae, J.-S.1
Yang, L.2
Rezaie, A.R.3
-
21
-
-
34147119744
-
The cytoprotective protein C pathway
-
Mosnier LO, Griffin JH. The cytoprotective protein C pathway. Blood 2007; 109: 3161-72.
-
(2007)
Blood
, vol.109
, pp. 3161-3172
-
-
Mosnier, L.O.1
Griffin, J.H.2
-
22
-
-
0036625064
-
Antithrombin III inhibits nuclear κB activation in human monocytes and vascular endothelial cells
-
Oleschlager C, Romisch J, Staubitz A, Stauss H, Leithauser B, Tillmanns H, Holschermann H. Antithrombin III inhibits nuclear κB activation in human monocytes and vascular endothelial cells. Blood 2002; 99: 4015-20.
-
(2002)
Blood
, vol.99
, pp. 4015-4020
-
-
Oleschlager, C.1
Romisch, J.2
Staubitz, A.3
Stauss, H.4
Leithauser, B.5
Tillmanns, H.6
Holschermann, H.7
-
23
-
-
0032475975
-
Phosphorylation of the cytoplasmic tail of syndecan-4 regulates activation of protein kinase Cα
-
Horowitz A, Simons M. Phosphorylation of the cytoplasmic tail of syndecan-4 regulates activation of protein kinase Cα. J Biol Chem 1998; 273: 25548-51.
-
(1998)
J Biol Chem
, vol.273
, pp. 25548-25551
-
-
Horowitz, A.1
Simons, M.2
-
24
-
-
20444443508
-
Activated protein C mediates novel lung endothelial barrier enhancement: Role of sphingosine 1-phosphate receptor transactivation
-
Finigan JH, Dudek SM, Singleton PA, Chiang ET, Jacobson JR, Camp SM, Ye SQ, Garcia JG. Activated protein C mediates novel lung endothelial barrier enhancement: Role of sphingosine 1-phosphate receptor transactivation. J Biol Chem 2005; 280: 17286-93.
-
(2005)
J Biol Chem
, vol.280
, pp. 17286-17293
-
-
Finigan, J.H.1
Dudek, S.M.2
Singleton, P.A.3
Chiang, E.T.4
Jacobson, J.R.5
Camp, S.M.6
Ye, S.Q.7
Garcia, J.G.8
-
25
-
-
31344451275
-
High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: Efficacy and safety
-
Wiedermann CJ, Hofmann JN, Juers M, Ostermann H, Kienast J, Briegel J, Strauss R, Keinecke H-O, Warren BL, Opal SM, for the KyberSept Investigators. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: Efficacy and safety. Crit Care Med 2006; 34: 285-92.
-
(2006)
Crit Care Med
, vol.34
, pp. 285-292
-
-
Wiedermann, C.J.1
Hofmann, J.N.2
Juers, M.3
Ostermann, H.4
Kienast, J.5
Briegel, J.6
Strauss, R.7
Keinecke, H.-O.8
Warren, B.L.9
Opal, S.M.10
-
26
-
-
34948866150
-
Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C
-
Kerschen EJ, Fernandez JA, Cooley BC, Yang XV, Sood R, Mosnier LO, Castellino FJ, Mackman N, Griffin JH, Weiler H. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med 2007; 204: 2439-48.
-
(2007)
J Exp Med
, vol.204
, pp. 2439-2448
-
-
Kerschen, E.J.1
Fernandez, J.A.2
Cooley, B.C.3
Yang, X.V.4
Sood, R.5
Mosnier, L.O.6
Castellino, F.J.7
Mackman, N.8
Griffin, J.H.9
Weiler, H.10
-
27
-
-
0028281746
-
Engineering plasminogen activator inhibitor 1 mutants with increased functional stability
-
Lawrence DA, Olson ST, Palaniappan S, Ginsburg D. Engineering plasminogen activator inhibitor 1 mutants with increased functional stability. Biochemistry 1994; 33: 3643-8.
-
(1994)
Biochemistry
, vol.33
, pp. 3643-3648
-
-
Lawrence, D.A.1
Olson, S.T.2
Palaniappan, S.3
Ginsburg, D.4
-
28
-
-
0031588685
-
The 2.6 Åstructure of antithrombin indicates a conformational change at the heparin binding site
-
Skinner R, Abrahams J-P, Whisstock JC, Lesk AM, Carrell RW, Wardell MR. The 2.6 Åstructure of antithrombin indicates a conformational change at the heparin binding site. J Mol Biol 1997; 266: 601-9.
-
(1997)
J Mol Biol
, vol.266
, pp. 601-609
-
-
Skinner, R.1
Abrahams, J.-P.2
Whisstock, J.C.3
Lesk, A.M.4
Carrell, R.W.5
Wardell, M.R.6
|